ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition...
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding...